Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (117,333,000)	$ 125,664,000	$ (368,445,000)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation, amortization and accretion	3,528,000	4,158,000	13,276,000
Stock-based compensation expense	4,847,000	5,135,000	8,725,000
Change in fair value of warrant liability	(5,488,000)	(5,369,000)
Loss (gain) on foreign currency translation	13,641,000	(3,433,000)	2,697,000
Loss (gain) on extinguishment of debt	1,611,000	(72,024,000)	1,049,000
Interest incurred through borrowings under Sanofi Loan Facility		4,478,000	1,652,000
Interest on note payable to principal stockholder	3,782,000	2,901,000	2,894,000
Series A warrant issuance cost		653,000
Other, net	100,000	19,000
(Gain) loss on sale, abandonment/disposal or impairment of property and equipment	203,000	1,259,000	140,582,000
(Gain) loss on purchase commitments	(215,000)	(2,265,000)	66,167,000
Write-off of inventory	2,971,000	0	36,104,000
Changes in operating assets and liabilities:
Accounts receivable, net	(2,487,000)	(302,000)
Receivable from Sanofi	30,557,000	(30,534,000)
Inventory	(3,297,000)	(2,331,000)	(26,434,000)
Receivable from collaboration			50,413,000
Deferred costs from commercial product sales	(96,000)	(309,000)
Deferred costs from collaboration		13,539,000	(13,539,000)
Prepaid expenses and other current assets	1,354,000	(346,000)	13,481,000
Other assets	188,000	361,000	150,000
Accounts payable	3,800,000	(12,118,000)	8,413,000
Accrued expenses and other current liabilities	2,932,000	348,000	(12,467,000)
Deferred revenue	(381,000)	3,419,000
Deferred payments from collaboration	(250,000)	(134,056,000)	950,000
Deferred sales from collaboration		(17,503,000)	17,067,000
Recognized loss on purchase commitments	(4,745,000)	40,566,000
Milestone rights liability and other liabilities			33,000
Net cash used in operating activities	(64,778,000)	(78,090,000)	(57,232,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,144,000)	(10,285,000)
Net proceeds from sale of asset held for sale	16,651,000
Proceeds from sale of property and equipment	24,000	17,000	82,000
Net cash provided by (used in) investing activities	16,675,000	(1,127,000)	(10,203,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from direct placement of common stock	61,000,000	50,000,000
Issuance cost associated with direct placement	(3,310,000)	(2,690,000)
Principal payments on facility financing obligation	(4,000,000)	(5,000,000)
Payment of employment taxes related to vested restricted stock units	(127,000)	(165,000)	(1,858,000)
Proceeds from issuance of common stock		893,000	4,146,000
Exercise of warrants for common stock		0	10,123,000
Payment of senior convertible notes			(64,287,000)
Payment of debt issuance costs on senior convertible notes			(831,000)
Borrowings on note payable to principal stockholder	19,429,000
Milestone payment			(4,219,000)
Proceeds from issuance of common stock pursuant to at-the-market issuance	564,000		28,392,000
Issuance costs	(17,000)		(548,000)
Other	24,000		40,000
Net cash provided by financing activities	73,563,000	43,038,000	5,668,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	25,460,000	(36,179,000)	(61,767,000)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	22,895,000	59,074,000	120,841,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	48,355,000	22,895,000	59,074,000
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Income taxes paid in cash	51,000
Interest paid in cash, net of amounts capitalized	7,728,000	8,991,000	13,355,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of note obligations and interest through issuance of common stock	20,593,000		8,253,000
Non-cash construction in progress and property and equipment		588,000
Reclassification of deferred payments from collaboration to Sanofi Loan Facility and loss share obligation		5,174,000	59,337,000
Reclassification of property and equipment to asset held for sale		$ 17,294,000
Capitalization of interest on note payable to principal stockholder	10,716,000
Reclassification of warrant liability to additional paid-in capital	$ 1,880,000
TEL AVIV STOCK EXCHANGE
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			36,142,000
Issuance costs			$ (1,432,000)